Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is the benefit of treating patients with cirrhosis proven?

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2016

Bruno Savino, Boccaccio Vincenzo, Russo Maria Luisa, Maisonneuve Patrick

Abstract excerpt

Hepatitis C virus (HCV)-related cirrhosis is an extremely heterogeneous pathological condition with a wide spectrum of clinical manifestations, ranging from pre-clinical to compensated and decompensated stages, each of which is characterized by a different clinical outcome. To measure the benefit of a sustained virological response (SVR) with interferon (IFN)-based therapy, several studies have been performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to End Stage Liver Disease

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 26725893
DOI: 10.1111/liv.13013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is the benefit of treating patients with cirrhosis proven?PMID 26725893Read ↗

Preparing the patient for success: treat or wait?Semantic proximity Read ↗

[Hepatitis C virus: 25 years-old, the end?].Semantic proximity Read ↗

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.Semantic proximity Read ↗

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.Semantic proximity Read ↗

Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.Semantic proximity Read ↗

Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.Semantic proximity Read ↗

Why I do not treat patients for mild disease.Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.Semantic proximity Read ↗

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.Semantic proximity Read ↗

Why do I treat my patients with mild hepatitis C?Semantic proximity Read ↗

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.Semantic proximity Read ↗

Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.